Brian Zeglis

Professor Brian Zeglis is a distinguished faculty member in the Department of Chemistry at Hunter College, where he brings a wealth of knowledge and expertise to his teaching and research endeavors. He earned his Bachelor of Arts degree from Yale University, followed by a Doctor of Philosophy from the prestigious California Institute of Technology. Further honing his skills, Professor Zeglis completed a postdoctoral fellowship at the renowned Memorial Sloan Kettering Cancer Center. In his role at Hunter College, Professor Zeglis is dedicated to educating students in the field of inorganic chemistry, imparting both foundational knowledge and advanced concepts. His research interests are broad and interdisciplinary, encompassing biochemistry, organic chemistry, inorganic chemistry, and radiochemistry. At the Zeglis Laboratory, his research is at the forefront of designing, synthesizing, and translating innovative pharmaceuticals for imaging and therapeutic applications. Professor Zeglis's work is particularly focused on the exciting fields of molecular imaging and bioorthogonal chemistry. His research aims to develop cutting-edge strategies for cancer imaging and therapy, which includes the creation of site-specific immunoconjugates. These efforts are crucial in advancing the precision and efficacy of cancer treatments. In addition to his work on immunoconjugates, Professor Zeglis is exploring the potential of optical imaging agents, which hold promise for enhancing the visualization of biological processes in real-time. His investigations also delve into the complex interactions between radioimmunoconjugates and the immune system, seeking to uncover new insights that could lead to improved therapeutic outcomes. Through his innovative research and commitment to education, Professor Zeglis is making significant contributions to the field of chemistry, with a particular emphasis on the development of novel approaches to imaging and therapy. His work not only advances scientific understanding but also holds the potential to impact patient care and treatment strategies in meaningful ways.